RAS依存がんの脆弱性を発見し,薬剤を投与する
1Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. sawyersc@mskcc.org
Cell
|June 4, 2009
まとめ
キナーゼ阻害剤を用いた標的がん治療は拡大している. 新しい研究は,RAS変異の腫瘍におけるキナーゼ特異の脆弱性を明らかにし,特定のキナーゼ変異の癌を超えて治療選択肢を拡大する可能性がある.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- ドラッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー・ドリッグ・ディスカバリー
背景:
- キナーゼ阻害剤は,標的がん治療における重要な進歩を意味します.
- 現在の応用は,腫瘍性キナーゼ変異を特定できるがんに限られている.
- RAS変異は多くのがんに共通しているが,特定の標的治療法がない.
研究 の 目的:
- RAS変異を宿す腫瘍におけるキナーゼ特有の脆弱性を調査する.
- キナーゼ阻害剤の治療の可能性を拡大する.
主な方法:
- RAS変異がんモデルにおける分子経路の調査.
- 特定されたキナーゼ依存性.
主要な成果:
- RAS変異性腫瘍における以前に未知のキナーゼ特異的脆弱性を発見した.
- ターゲットを絞った阻害のための実証された可能性.
結論:
- キナーゼ阻害剤は,RAS変異を有するがんを含む,より幅広い種類のがんに対して有効である可能性があります.
- 発見は,腫瘍学における新しい治療戦略の道を開く.
関連する概念動画
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...


